Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles

Open Access

Review Article

Drug interaction and its implication in clinical practice and personalized medicine

Abdullahi Rabiu Abubakar, Bashir AZ Chedi, Khalid Garba Mohammed, Mainul Haque.

In personalized medicine, the appropriate drugs for an individual patient are selected based on the patient’s medical history, diagnostic testing, and genetic information for the purpose of minimizing drug interactions (DIs), side effects, and adverse drug reactions (ADRs) and of obtaining the maximum therapeutic benefit. The DI is one of the major problems of pharmacotherapy, which perhaps leads to adverse outcome or therapeutic failure if not properly addressed. In clinical practice, patient safety is likely to improve through the identification of frequently occurring DIs by pharmacist and notifying the other members of the health-care team. Recently, a software was introduced, which detects DIs with good precision; however, this software requires a constant update. Health-care professionals require adequate knowledge and skills on how to identify and avoid DIs to enable them complement the software assessment. Basically, DIs include drug–drug, drug–food, drug–herbal, and drug–disease interactions. These possibilities can be identified from chemical properties, pharmacokinetics, and pharmacodynamics of the drug, patient medical history, concomitant disease, or organ failure. Focusing on DIs will help to reduce drug-related problems, advance the evidence-based medicine, and improve the level of patient satisfaction. Adequate knowledge of drug DIs will enable the health-care professionals to individualize the patient treatment in order to get maximum therapeutic benefit. This script is aimed at describing the various classes of DIs, their causes, and their implications in clinical practice and patient safety.

Key words: Drug Interactions; Pharmacokinetics; Food; Herbal; Disease

Similar Articles

Dysbalance of ACE2 levels - a possible cause for severe COVID-19 outcome in COPD.
FlieĂźer E, Birnhuber A, Marsh LM, Gschwandtner E, Klepetko W, Olschewski H, Kwapiszewska G
The journal of pathology. Clinical research. 2021; ():

Proteomic analysis of oilseed cake: a comparative study of species-specific proteins and peptides extracted from ten seed species.
Kotecka-Majchrzak K, Sumara A, Fornal E, Montowska M
Journal of the science of food and agriculture. 2021; 101(1): 297-306

coinfection as source of pyogenic liver abscess.
Burch J, Tatineni S, Enofe I, Laird-Fick H
BMJ case reports. 2021; 14(5):

Alternative and Improved Stability-Indicating HPLC Method for the Assay of Eprinomectin and Determination of its Related Compounds in Bulk Batches of Eprinomectin Drug Substance.
Padivitage N, Tian J, Rustum A
Journal of AOAC International. 2021; ():

Recent Advances in Food Emulsions and Engineering Foodstuffs Using Plant-Based Nanocelluloses.
Bai L, Huan S, Zhu Y, Chu G, McClements DJ, Rojas OJ
Annual review of food science and technology. 2021; 12(): 383-406

Full-text options

Add your Article(s) to Indexes
• CiteIndex: Articles & Statistics

American Journal of Diagnostic Imaging


Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.